Introduction - PCSK9 inhibition: science, outcomes and guidance.
Topic:
Tobacco
Organised by PACE-CME - Physicians' Academy for Cardiovascular Education, supported with educational grants provided by Amgen and Sanofi-Regeneron
Event:
ESC Congress 2018
Congress Presentation
About the speakers
Professor Philip Barter
University of New South Wales Sydney, Sydney (Australia)
6
presentations
0
follower
Professor John Kastelein
Faculty of Medecine - University of Amsterdam, Amsterdam (Netherlands (The))
32
presentations
4
followers
4 more presentations in this session
PCSK9 as target for treatment: the genetic validation.
Speaker: Professor B. Ference (Cambridge, GB)
Novel PCSK9 outcomes in perspective: lessons from FOURIER & ODYSSEY.
Speaker: Doctor J. Robinson (Iowa, US)
Targeting PCSK9 in clinical practice: guidance and future.
Speaker: Professor J. Kastelein (Amsterdam, NL)
Discussion and summary - PCSK9 inhibition: science, outcomes and guidance
Speaker: Professor P. Barter (Sydney, AU)
Access the full session
PCSK9 inhibition: science, outcomes and guidance (EBAC Accredited)
Speakers:
Professor P. Barter, Professor J. Kastelein, Professor B. Ference, Doctor J. Robinson, Professor J. Kastelein...
About the event
ESC 365 is supported by
